Lantheus (NASDAQ:LNTH) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Lantheus Stock Down 0.3%

Lantheus stock traded down $0.35 during midday trading on Thursday, hitting $101.25. 1,193,845 shares of the stock were exchanged, compared to its average volume of 1,084,147. Lantheus Holdings, Inc. has a 52-week low of $51.47 and a 52-week high of $111.86. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 24.94 and a beta of 0.01. The business’s 50-day moving average price is $100.30 and its 200-day moving average price is $92.57. The company has a quick ratio of 3.06, a current ratio of 3.25 and a debt-to-equity ratio of 0.42.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 EPS for the quarter, topping the consensus estimate of $1.23 by $0.45. The firm had revenue of $389.91 million for the quarter, compared to analysts’ expectations of $355.74 million. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.27 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on LNTH. William Blair set a $102.50 target price on shares of Lantheus in a research note on Monday, August 3rd. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, October 15th. Truist Financial cut Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Three analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $107.44.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LNTH. Western Wealth Management LLC bought a new stake in Lantheus during the 1st quarter worth approximately $25,000. Bessemer Group Inc. boosted its holdings in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the period. USA Financial Formulas bought a new position in Lantheus in the 3rd quarter valued at $41,000. Allworth Financial LP bought a new position in Lantheus in the 2nd quarter valued at $49,000. Finally, Farther Finance Advisors LLC grew its position in shares of Lantheus by 122.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Lantheus Company Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.